Nanomedicine

Inert inorganic particles reach selected tumour cells

Upon X-ray radiation (hν(X)), NanoXray particles emit electrons (e-) that in...
Upon X-ray radiation (hν(X)), NanoXray particles emit electrons (e-) that in turn lead to the formation of radicals (R°) that damage DNA molecules and other cell components

Radiotherapy is a treatment of choice for six million (60%) of cancer patients annually. However, it has a crucial deficit: its therapeutic window is limited. The reason is simple. While radiotherapy is very efficient in killing cancer cells, it inevitably also damages surrounding healthy tissue. Therefore, in many cases doctors need to restrict the dose - a compromise that prevents the effective eradication of tumour cells.

For decades, radiotherapists have not been able to greatly improve the situation. They believe that even a 5-20% increase in the therapeutic window could drastically change clinical output. French nanomedicine specialist Nanobiotix has developed NanoXray, a formulation of inert, inorganic particles with a size of 50nm that can be delivered selectively to tumour cells. Consisting of hafnium oxide, they react to a standard radiation dose by emitting a shower of electrons. This is the identical physical mode of action of radiotherapy – except that hafnium oxide emits far more electrons than a water molecule, the usual target, and thereby locally increases the effective dose by a factor of nine. The radiotherapy dose in the surrounding healthy tissue is unaffected because it is not loaded with nanoparticles.

NanoXray can be administered without the need to invest in novel devices; it does not even require changes in standard radiation procedures. NanoXray is applied either via intra-tumoural injection (NBTXR3) or by deposition of a gel-formulation in the tumour bed during surgical resection (NBTX-TOPO). A formulation for intravenous injection (NBTXIV) is also in development.

EU regulated as a medical device, NBTXR3 is in a Phase I study in soft tissue sarcoma patients. Preliminary results are expected at the end of 2012.

05.11.2012

More on the subject:
Read all latest stories

Related articles

Photo

Promising metabolite

Gut flora could hold the key for new diabetes treatments

An organic compound produced by the gut flora – the metabolite 4-Cresol – is considered to have protective effects against both type 1 and 2 diabetes, notably by stimulating the growth of the…

Photo

Zooming in

Breast cancer map reveals how mutations shape the tumour landscape

Scientists have created one of the most detailed maps of breast cancer ever achieved, revealing how genetic changes shape the physical tumour landscape. An international team of scientists, brought…

Photo

Gastroenterology

Crohn's disease linked to increased risk of colorectal cancer

Researchers from Karolinska Institutet, Örebro University and Aarhus University, Denmark, have published the largest study to date on the risk of colorectal cancer in Crohn's disease. The article is…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH